Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines by utilizing its proprietary proteomics-based patient responder identification platform. Co.'s Clinical Candidate ACR-368 is a selective small molecule inhibitor targeting CHK1 and CHK2. Using its Acrivon Predictive Precision Proteomics (AP3) platform, Co. has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature that can predict patient response to ACR-368 monotherapy. Co. also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. The ACRV average annual return since 2022 is shown above.
The Average Annual Return on the ACRV average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACRV average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACRV average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|